On April 8, 2009, Genentech, the manufacturer of the psoriasis drug Raptiva (efalizumab), announced that it had begun a withdrawal of Raptiva from the U.S. market because of its link to patients developing progressive multifocal leukoencephalopathy (PML), a neurologic disease caused by a virus that affects the central nervous system. PML is associated with long-term [...]
Mail this post
Read More...
Product Liability Lawyer News